Spark Impact

Diagnostic Healthcare Ltd, an Altrincham, UK-based diagnostic imaging company. Led by Liat Karni, managing director, and Michael Ringart, chairman, Diagnostic Healthcare has a network of centres and mobile units across the UK providing MRI scans, obstetric ultrasound, bone density scans (DEXA scan), cardiac testing, health screening and reporting services. The company offers end-to-end integrated solutions, either as mobile services or located within hospitals, GP surgeries or dedicated community sites.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

Renephra Ltd. is a medical device company based in Manchester, United Kingdom, established in 2009. It specializes in developing innovative Transdermal Fluid Removal (TFR) technology aimed at addressing fluid overload and chronic conditions such as oedema and lymphoedema. The company's devices utilize a micro-needle system combined with negative pressure therapy to facilitate minimally invasive fluid removal from the skin. This technology targets significant clinical needs within vascular and oncology patients, representing a large and underserved market estimated at £1 billion globally. Having achieved proof of concept in human trials, Renephra is currently seeking funding to advance its device development and feasibility studies.

Ai2, Ltd. engages in the development of technology products to prevent infection on various commonly used medical devices. Its products include coated hydrogels for use in catheter, lens, and implant applications; artificial joints to prevent contamination and colonisation of orthopaedic implants by microbes; endotracheal tubes to protect endotracheal tubes from colonisation by microbes; wound dressings to confer anti-infective properties on wound dressing materials; urinary catheters to prevent colonisation by bacteria and other microbes; and vascular catheters. The company's products are human protein-like substances to inhibit bacteria, fungi, and viruses on medical devices, such as urinary catheters, stents, and wound dressings. It serves healthcare companies in the United States and Europe. Ai2, Ltd. was founded in 2004 and is based in Manchester, the United Kingdom.